ASSESSMENT OF FEBRILE NEUTROPENIA EPISODES IN CHILDREN WITH ACUTE LEUKEMIA TREATED WITH BFM PROTOCOLS

REFERENCES

• Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer: a prospective study of 1001 episodes. Medicine 1982; 61: 153–165
   PubMed Web of Science ®Google Scholar
• Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328: 1323–1332
   PubMed Web of Science ®Google Scholar
• Hann I, Viscoli C, Paesmans M, et al. A comparison of outcome from febrile neutropenic episodes in children compared with adults: results from four EORTC studies. International Antimicrobial Therapy Cooperative Group (IATCG) of the European Organization for Research and Treatment of Cancer (EORTC). Br J Haematol 1997; 99: 580–588
   PubMed Web of Science ®Google Scholar
• Quadri TL, Brown AE. Infectious complications in the critically ill patient with cancer. Semin Oncol 2000; 27: 335–346
   PubMed Web of Science ®Google Scholar
• Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol 2002; 24: 38–42
   PubMed Web of Science ®Google Scholar
• West DC, Marcin JP, Mawis R, et al. Children with cancer, fever, and treatment-induced neutropenia: risk factors associated with illness requiring the administration of critical care therapies. Pediatr Emerg Care 2004; 20: 79–84
   PubMedGoogle Scholar
• Basu SK, Fernandez ID, Fisher SG, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005; 23: 7958–7966
   PubMed Web of Science ®Google Scholar
• Jones GR, Konsler GK, Dunaway RP, et al. Risk factors for recurrent fever after the discontinuation of empiric antibiotic therapy for fever and neutropenia in pediatric patients with a malignancy or hematologic condition. J Pediatr 1994; 124: 703–708
   PubMedGoogle Scholar
• Schrappe M, Reiter M, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000; 14: 2205–2222
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030–2042
   PubMed Web of Science ®Google Scholar
• Hughes WT, Armstrong D, Bodey GP, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751
   PubMed Web of Science ®Google Scholar
• Link H, Böhme A, Cornely OA, et al. Antimicrobial therapy of unexplained fever in neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO), Study Group Interventional Therapy of Unexplained Fever, Arbeitsgemeinschaft Supportivmassnahmen in der Onkologie (ASO) of the Deutsche Krebsgesellschaft (DKG-German Cancer Society). Ann Hematol 2003; 82(Suppl 2)S105–117
   Google Scholar
• Mayordomo JI, Rivera F, Díaz-Puente MT, et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 1995; 87: 803–808
   PubMed Web of Science ®Google Scholar
• Orudjev E, Lange BJ. Evolving concepts of management of febrile neutropenia in children with cancer. Med Pediatr Oncol 2002; 39: 77–85
   PubMedGoogle Scholar
• Santolaya ME, Alvarez AM, Becker A, et al. Prospective, multicenter evaluation of risk factors associated with invasive bacterial infection in children with cancer, neutropenia, and fever. J Clin Oncol 2001; 19: 3415–3421
   PubMed Web of Science ®Google Scholar
• Rondinelli PI, Ribeiro Kde C, de Camargo B. A proposed score for predicting severe infection complications in children with chemotherapy-induced febrile neutropenia. J Pediatr Hematol Oncol 2006; 28: 665–670
   PubMed Web of Science ®Google Scholar
• Reilly A. Infections in children with cancer-old approaches and new. Eur J Cancer 2003; 39: 652–653
   PubMedGoogle Scholar
• Chanock SJ, Pizzo PA. Infectious complications of patients undergoing therapy for acute leukemia: current status and future prospects. Semin Oncol 1997; 24: 132–140
   PubMed Web of Science ®Google Scholar
• Ammann RA, Aebi C, Hirt A. Fever in neutropenia in children and adolescents: evolution over time of main characteristics in a single center, 1993–2001. Support Care Cancer 2004; 12: 826–832
   PubMedGoogle Scholar
• Tezcan G, Küpesiz A, Özturk F, et al. Episodes of fever and neutropenia in children with cancer in a tertiary care medical center in Turkey. Pediatr Hematol Oncol 2006; 23: 217–29
   PubMed Web of Science ®Google Scholar
• Aksoylar S, Çetingül N, Kantar M, et al. Meropenem plus amikacin versus piperacillin–tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol 2004; 21: 115–123
   PubMed Web of Science ®Google Scholar
• Gençer S, Salepci T, Ozer S. Evaluation of infectious etiology and prognostic risk factors of febrile episodes in neutropenic cancer patients. J Infect 2003; 47: 65–72
   PubMed Web of Science ®Google Scholar
• Ağaoğlu L, Devecioğlu O, Anak S, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001; 13: 281–287
   PubMed Web of Science ®Google Scholar
• Auletta JJ, O’Riordan MA, Nieder ML. Infections in children with cancer: a continued need for the comprehensive physical examination. J Pediatr Hematol Oncol 1999; 21: 501–508
   PubMed Web of Science ®Google Scholar
• Greenberg D, Moser A, Yagupsky P, et al. Microbiological spectrum and susceptibility patterns of pathogens causing bacteraemia in paediatric febrile neutropenic oncology patients: comparison between two consecutive time periods with use of different antibiotic treatment protocols. Int J Antimicrob Agents 2005; 25: 469–473
   PubMedGoogle Scholar
• Gibson J, Johnson L, Snowdon L, et al. Trends in bacterial infections in febrile neutropenic patients: 1986–1992. Aust N Z J Med 1994; 24: 374–377
   PubMedGoogle Scholar
• Aledo A, Heller G, Ren L, Gardner S, et al. Septicemia and septic shock in pediatric patients: 140 consecutive cases on a pediatric hematology-oncology service. J Pediatr Hematol Oncol 1998; 20: 215–221
   PubMed Web of Science ®Google Scholar
• Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. Blood 2000; 95: 3310–3322
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Varwig D, Kaiser J, et al. Infectious complications in children with AML: analysis of the AML-BFM 93 clinical trial. Blood 2002; 100: 244b, [abstr]
   Google Scholar
• Müller J, Garami M, Constantin T, et al. Meropenem in the treatment of febrile neutropenic children. Pediatr Hematol Oncol 2005; 22: 277–284
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995; 13: 165–176
   PubMed Web of Science ®Google Scholar
• Sanders JW, Powe NR, Moore RD. Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 1991; 164: 907–916
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994; 12: 2471–2508
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 2005; 23: 4198–4214
   PubMed Web of Science ®Google Scholar
• Sasse EC, Sasse AD, Brandalise S, et al. Colony stimulating factors for prevention of myelosupressive therapy induced febrile neutropenia in children with acute lymphoblastic leukaemia. Cochrane Database Syst Rev 2005; 3: CD004139
   Google Scholar
• Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22: 3350–3356
   PubMed Web of Science ®Google Scholar
• Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol 2006; 24: 4499–4506
   PubMed Web of Science ®Google Scholar